Literature DB >> 3132953

HIV-2 antisera cross-neutralize HIV-1.

R A Weiss1, P R Clapham, J N Weber, D Whitby, R S Tedder, T O'Connor, S Chamaret, L Montagnier.   

Abstract

The neutralization properties of three independent HIV-2 isolates were examined in comparison with four diverse HIV-1 strains. Human sera containing antibodies specific to HIV-2 can cross-neutralize HIV-1. By contrast, HIV-1 sera are group-specific and have no neutralizing effect on HIV-2. Therefore, HIV-2 antigens may be important components for the development of broadly cross-protective AIDS vaccines.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3132953     DOI： 10.1097/00002030-198804000-00004

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  21 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.

Authors:  A McKnight; C Shotton; J Cordell; I Jones; G Simmons; P R Clapham
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

4.  Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site.

Authors:  B Böttiger; A Karlsson; P A Andreasson; A Nauclér; C M Costa; E Norrby; G Biberfeld
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

5.  Comparison of cervicovaginal humoral immunity in clinically asymptomatic (CDC A1 and A2 category) patients with HIV-1 and HIV-2 infection.

Authors:  L Bélec; C Tévi-Bénissan; T Dupré; A S Mohamed; T Prazuck; J Gilquin; J M Kanga; J Pillot
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

6.  Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.

Authors:  Rui Kong; Hui Li; Frederic Bibollet-Ruche; Julie M Decker; Natalie N Zheng; Geoffrey S Gottlieb; Nancy B Kiviat; Papa Salif Sow; Ivelin Georgiev; Beatrice H Hahn; Peter D Kwong; James E Robinson; George M Shaw
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

7.  Cloning, expression, and purification of HIV-2 gp125: A target for HIV vaccination.

Authors:  Samer Sourial; Anette Wärnmark; Charlotta Nilsson; Ewa Björling; Adnane Achour; Robert A Harris
Journal:  Mol Biotechnol       Date:  2005-06       Impact factor: 2.695

8.  High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Authors:  Katie L Davis; Elin S Gray; Penny L Moore; Julie M Decker; Aidy Salomon; David C Montefiori; Barney S Graham; Michael C Keefer; Abraham Pinter; Lynn Morris; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

Review 9.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

10.  Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.

Authors:  M Robert-Guroff; K Aldrich; R Muldoon; T L Stern; G P Bansal; T J Matthews; P D Markham; R C Gallo; G Franchini
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.